Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

This study has been completed.
Sponsor:
Collaborators:
Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)
Astrazeneca (direct)
InfraReDx (indirect)
Information provided by (Responsible Party):
Annapoorna Kini, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01837823
First received: April 5, 2013
Last updated: August 9, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)